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To my dear children and parents, with love

ABSTRACT 
Cryopreservation of human ovarian tissue is one approach to preserve fertility for 
women who can be predicted to undergo premature ovarian failure as a consequence of 
chemotherapy, radiotherapy or genetic disorders. It is the most suitable option for pre-
pubertal girls and for many young women to store oocytes.  To date, auto-
transplantation of frozen- thawed cortical tissues has resulted in birth of 24 healthy 
children, worldwide. Cryopreservation can be performed using slow freezing or 
vitrification. Vitrification is known as solidification without formation of lethal 
intracellular ice crystals. The aim of this thesis was to further develop methods for 
cryopreserving follicles in human ovarian tissue of women who have a risk of losing 
their fertility.  
 
In the first study, we systematically compared two cryopreservation methods for human 
ovarian cortical tissue, slow freezing and vitrification. Cryoprotectants we used for 
slow freezing were either 1,2- propanediol (PrOH)- sucrose or ethylene glycol (EG)-
sucrose. For vitrification, we used solutions containing a combination of the 
cryoprotectants dimethyl sulphoxide (DMSO), PrOH, EG and polyvinylpyrrolidone 
(PVP). Light microscopy (LM), transmission electron microscopy (TEM) and post-
thaw tissue culture were carried out to evaluate the structure and the viability of the 
follicles. The follicles were well preserved and the ovarian stroma showed better 
morphological integrity after vitrification. In the second study, we developed a clinical 
grade vitrification of human ovarian tissue. Ovarian tissue was vitrified in a closed 
system without any direct contact with liquid nitrogen using a non-toxic and sterile 
cryotube.  Vitrification solutions used contained a combination of cryoprotectants 
DMSO, PrOH, EG and PVP. The morphology of the follicles in the vitrified tissue, 
showed well -preserved structures as verified by LM, TEM and also after post -thaw 
culture. The system used is compatible with the European tissue directive and the 
Swedish tissue law. In the third article, we studied the occurrence of apoptosis in 
vitrified tissues. We used Terminal deoxynucleotidyl transferase dUTP nick end 
labeling (TUNEL) assay and DNA fragmentation analysis, which showed no incidence 
of apoptosis in follicles or stroma after using either vitrification solution (i.e., a 
combination of DMSO, PrOH, EG and PVP, or EG and bovine serum albumin (BSA). 
In the fourth one, we performed a study to simplify our earlier described closed 
vitrification procedure. Permeating cryoprotectants used in vitrification solutions 
consisted either of a combination of DMSO, PrOH, EG or EG only. Ovarian tissue was 
vitrified in closed sealed tubes containing either of the vitrification solutions. 
Morphological analysis (LM and TEM) showed that oocytes, granulosa cells and 
stroma were equally well preserved when either of the vitrification solutions was used. 
No apoptosis was observed in primordial and primary follicles using 
immunohistochemistry for active caspase- 3. Conclusion: Hereby we present new 
vitrification procedures that can be performed in a clinical setting. The morphology of 
follicles in the ovarian tissue as evaluated by using LM and TEM proved to be normal 
after the procedures. Ultra-structural analysis by TEM used in this study is the best-
known method to evaluate cryoinjury. We have developed a new effective clinical 
grade method for cryo-storage of human ovarian tissue.  
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1 INTRODUCTION 
Infertility is a significant public health problem that affects about 15% of couples of 
fertile age worldwide. There are large numbers of factors, which cause infertility. One 
cause is cancer treatment. Ovarian damage is a common side effect of chemotherapy 
and radiotherapy for women and girls who are after such treatment at a risk of losing 
their germ cells (Nicosia et al. 1985; Wallace et al. 1989; Howell and Shalet 1998; 
Schmidt et al. 2010). There are also genetic causes.  Follicles in girls with Turner’s 
syndrome, for instance, disappear prematurely often before 20 years of age (Hreinsson 
et al. 2002; Borgstrom et al. 2009).  
 
Sperm cryopreservation has been an option for men to preserve their reproductive 
capability before starting cancer treatment for over 60 years. The first successful human 
pregnancy using frozen sperm was obtained in 1953. Ovarian tissue cryopreservation 
has been a feasible method since 1996 with functioning tissue after thawing. It has been 
used for young women, including girls with Turner’s syndrome (Hovatta et al. 1996; 
Newton et al. 1996; Hreinsson et al. 2002). The first healthy child has been born after 
autologous re-transplantation of frozen-thawed tissue in 2004 (Donnez et al. 2004), and 
since then 24 children have been born (Dolmans et al. 2013). 
 
Cryopreservation of ovarian tissue is the most suitable technique for pre-pubertal and 
young women, who do not yet have mature oocytes for in vitro fertilization (IVF). The 
vast majority of immature ovarian follicles are situated in the ovarian cortex, and 
cryopreservation of this tissue also enables storing a large number of oocytes (Hovatta 
et al. 1996; Newton et al. 1996; Hreinsson et al. 2002).  
A cryopreservation procedure should ensure the viability of the follicles and minimize 
changes in morphology and ultra-structure.  Cells are exposed to different stresses 
caused by ice formation, during cooling and warming. These stresses vary due to the 
cryopreservation techniques used; slow freezing or vitrification (Karlsson and Toner 
1996; Mullen and Critser 2007). Until today, slow rate freezing has been mostly 
employed in clinical programmes. A new promising technique, vitrification of ovarian 
tissue, has received researchers’ considerable interest, first in experimental animals and 
then also in human (Li et al. 2007; Lornage and Salle 2007; Huang et al. 2008; Keros et 
al. 2009; Sheikhi et al. 2011).  
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2 REVIEW OF THE LITERATURE 
 
1.1 DEVELOPMENT OF OOCYTES AND OVARIAN FOLLICLES 
1.1.1 Ovarian reserve 
The pool of female germ cells is formed during foetal period. Female fertility potential 
can be measured by the ovarian reserve. Sperm production in male is a continuing 
process, but oocytes in postnatal life are non-renewable (Zuckerman, 1951; (Byskov et 
al. 2011). Even though opposing opinions have recently been presented (Johnson et al. 
2004; Johnson et al. 2005), the results have not been convincing, and they have not 
been repeatable (Gerner unpublished data). Neither has anybody else managed in 
culturing up oocytes from stem cells in ovarian stroma (Adhikari and Liu 2009; Byskov 
et al. 2011).  
The ovary contains a large number of oocytes surrounded by supporting somatic 
granulosa and theca cells that form a unit called follicle. The primordial follicles are 
embedded in stroma, the fibrous tissue in the ovary. Throughout the entire reproductive 
period of a woman, only 400-500 follicles become ovulated, whilst the rest degenerate 
(Gougeon 1996). The number of primordial follicles continually decreases by atresia at 
an exponential rate during reproductive life (Faddy et al. 1992; Faddy and Gosden 
1995; Faddy 2000). The two main tasks performed by the ovary consist of producing 
and housing fertilisable oocytes, and secreting of hormones that are responsible for 
follicle maturation and the appearance of secondary sex characteristics.   
 
 
1.1.2 Folliculogenesis 
Folliculogenesis is a process in which follicles are formed from primordial germ cells 
in the foetal ovary (Byskov et al. 2011), and later on when a resting follicle begins to 
grow and develop through the primordial, primary, secondary and tertiary (antral) 
stages into the ovulatory stage. The developing follicles are located within the ovarian 
cortex. There are four major events involved in the postnatal folliculogenesis, i.e., 
recruitment of follicles into the growing pool, preantral follicle growth and 
development, selection of one dominant follicle and maturation of the preovulatory 
follicle (Gougeon 2010).  
In the sexually mature female, primordial follicles, which have remained quiescent for 
years, are recruited little by little into the growing pool. Each month, a cohort of 
follicles grows under the influence of gonadotrophins. Normally only one of them 
ovulates under a complicated hormonally regulated process (Adhikari and Liu 2009). In 
response to a mid-cycle surge of luteinizing hormone (LH), one dominant follicle 
releases a mature oocyte ready to become fertilized (Gougeon 1996; McGee and Hsueh 
2000). At the antral stage, most follicles die by atresia while a few of them reach the 
pre-ovulatory stage supported by the pituitary gonadotrophins, follicle-stimulating 
hormone (FSH) and luteinising hormone (LH) (Gougeon 2010). 
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Follicular growth and maturation involve tight regulation of paracrine and endocrine 
signals.  It requires the coordinated communication between the oocyte and its somatic 
cell companions. Two key somatic cells in the ovary are granulosa cells and theca cells.  
Granulosa cells support the regulation of the oocyte development by providing 
nutrients and molecular signals, while the oocyte is needed for granulosa cells to 
proliferate and differentiate in addition to promoting the organisation of the follicle. 
The communication between oocytes and granulosa cells occurs via paracrine 
signalling and bi-directional gap junctions (Reddy et al. 2010). Gap junctions, channels 
through the plasma membrane, allow the exchange of molecules such as amino acids, 
second messenger cAMP and possibly energy metabolites such as glucose (Eppig 1991, 
1992).  
 
 
1.1.3 Oogenesis 
Oocytes in the ovarian follicles originate from primordial germ cells (PGC). During 
early embryonic development, PGCs move a short distance from the dorsal mesentery 
of the hindgut into the gonadal ridges at the beginning of the fifth week of gestation. 
They come to rest on either side of the coelomic angle and colonize the gonadal ridges 
(Mamsen et al. 2012). The colonization of the gonadal ridges occurs during the late 
fifth week or at the beginning of the sixth week of gestation. The PGCs continue to 
proliferate by mitosis and become rapidly surrounded by cords of somatic cells. During 
the ninth week, the differentiation of PGCs into oogonia occurs. In the human female, 
the PGCs enter meiosis at about 11-12 weeks of gestation (Mc et al. 1953; Fujimoto et 
al. 1977; Gondos et al. 1986; Ding et al. 2008; Mollgard et al. 2010). 
The primordial oocytes enter meiosis and become arrested in the prophase of the first 
meiotic division, transformed into primary oocytes. At the time of arrest, the primary 
oocytes become surrounded by a single layer of flat granulosa cells (GCs), forming 
primordial follicles. The total number of follicles reaches a peak of around seven 
million at 16-20 weeks of gestation in the female foetus. During follicle formation, 
many oocytes are lost by apoptosis. The number of follicles subsequently decreases to 
about one to two million at birth and 3-400.000 at menarche (Faddy et al. 1992; Faddy 
2000; Martins da Silva et al. 2004). The rate of follicular depletion accelerates from the 
age of 37 years onward, resulting in around 100-1000 follicles per ovary at menopause 
(Gougeon et al. 1994; Broekmans et al. 2007).  
 
 
1.1.4 Growth factors and hormones  
Transforming growth factor- beta (TGF-ß) superfamily 
Anti- Müllerian hormone (AMH), inhibins, activins, bone morphogenic proteins 
(BMPs) and growth differentiation factors (GDFs) belong to the Transforming 
growth factor- beta (TGF-ß) superfamily. These growth factors are known to be 
important in early follicular growth (Massague and Chen 2000) in the ovary.   
TGF-ß receptors exist in homo- or hetero-dimeric forms. They are single pass serine/ 
threonine kinase receptors. Receptor types I and II are two subfamilies of TGF-ß 
receptors distinguished by their structural and functional properties (Massague 1998).  
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AMH expression in ovarian tissue from healthy women was found to be highest in 
granulosa cells of secondary, preantral and small antral follicles (≥ 4mm) (Weenen et 
al. 2004). AMH is an important regulator of the initiation of growth of human 
primordial ovarian follicles (Carlsson et al. 2006), in a similar manner as it regulates 
follicular activation in rodents (Durlinger et al. 2002). 
 
The BMPs play a significant role during embryogenesis and in the maintenance and 
repair of bone and other tissue in the adult (Massague and Chen 2000). 
BMP receptors are located on the cell surface.  
 
GDF-9 is a paracrine factor essential for mammalian ovarian folliculogenesis and 
fertility. It is expressed in human oocytes during early development of follicle (Laitinen 
et al. 1998; Hreinsson et al. 2002; Mottershead et al. 2008). Hreinsson et al. in our 
group showed that GDF-9 promotes the activation of primordial follicles in human 
cultured ovarian tissue. A significantly higher proportion of primordial follicles showed 
growth initiation and reached secondary stage in presence of GDF-9 (Hreinsson et al. 
2002). 
 
Inhibins are hetero-dimeric glycoproteins consisting of one α -subunit and one ß –
subunit (de Kretser et al. 2002). They inhibit FSH secretion via a feedback regulatory 
mechanism.  Inhibin B levels are highest in the early follicular phase and decrease in 
the late follicular phase of a menstrual cycle, whereas inhibin A level is highest in the 
late follicular and luteal phases (Groome et al. 1996). In the ovary, inhibins and activins 
are produced by granulosa cells of all follicles. In women older than 40 years, a higher 
level of FSH in the follicular phase was associated with a decrease in total inhibin 
concentration in both follicular and luteal phases (MacNaughton et al. 1992). 
 
Activins are homo- or heterodimers consisting of two different, covalently linked, 
inhibin ß –subunits (ßA and ßB). There are three forms of activin including active A, 
activin AB and activin B. Activin is produced in granulosa cells of growing follicles 
(from primary to tertiary stage). It plays a role in promoting aromatase activity, the 
formation of antral cavity and proliferation of granulosa cells (Ying 1988; Thompson et 
al. 2005). The activity of activin is regulated by follistatin and inhibin that bind to its 
receptor and thereby mediate inhibition. Follistatin is a single chain polypeptide that is 
produced by the granulosa cells (Thompson et al. 2005). Activin has been used in 
promoting ovarian follicular growth in culture (Telfer et al. 2008). 
 
Follicle stimulating hormone (FSH)  
 
FSH is a gonadotrophin that stimulates the growth of antral follicles (Oktay et al. 
1997).  The initiation of follicular growth is gonadotrophin-independent, but FSH is 
still involved in early development of the follicles (Funkenstein et al. 1980). Shortly 
after initiation of growth, the follicles become responsive to FSH (Oktay et al. 1997).  
FSH receptors (FSHR) are present in granulosa cells of growing follicles from the 
primary up to the Graafian stage. FSH sensitivity plays an essential role in the selection 
of dominant follicle for ovulation (Funkenstein et al. 1980). Women with an 
inactivating mutation in the FSHR showed hyper-gonadotrophic ovarian dysgenesis, 
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amenorrhea and infertility. Follicles do not develop beyond the primary stage in these 
women (Aittomaki et al. 1996). 
 
  
1.2 OVARIAN TISSUE IN ANIMAL MODELS 
Animal models have been used to optimise cryopreservation protocols for human 
ovarian tissue. These could be applied directly to humans. Studies on mutant mice have 
given valuable information for understanding molecular mechanisms underlying human 
follicular activation (Adhikari and Liu 2009; Reddy et al. 2010). Long before the 
human studies, ovarian tissue from several animal species has been cryopreserved. In 
these experiments glycerol was used as a cryoprotectant and tissues were stored at -
79°C. Ovarian tissue from mice, rats and hamsters has been successfully cryopreserved. 
Transplantation of frozen- thawed mouse ovarian tissue (Deanesly, 1954; Green, et al., 
1956; Parkes; 1958) and isolated mouse primordial follicles from post-thawed ovarian 
tissue has resulted in live offspring (Carroll and Gosden 1993). Live births have been 
achieved after auto-transplantation of post-thawed ovarian tissues using slow freezing 
in sheep (Gosden et al. 1994). Since then, several successful studies regarding freezing 
of ovarian tissue from several animal species such as sheep (Almodin et al. 2004; Baird 
et al. 2004; Cecconi et al. 2004), goat (Rodrigues et al. 2004), zebu bovine (Lucci et al. 
2004) and cat (Bosch et al. 2004) have been carried out. 
Vitrification of ovarian tissue has been successfully used in mice with much looser 
ovarian structure than in humans (Salehnia et al. 2002; Tokieda et al. 2002; Wang et al. 
2008). In vitro maturation of vitrified mouse ovarian follicles has resulted in live births 
(Wang et al. 2011). Recently, vitrification has been reported as an advanced alternative 
method for cryopreservation of ovarian tissue with improved viability of vitrified 
tissue, in various species including; mouse (Wang et al. 2009), rat (Deng et al. 2009), 
pig (Gandolfi et al. 2006), goat (Santos et al. 2007), sheep (Courbiere et al. 2006) and 
monkey (Yeoman et al. 2005; Hashimoto et al. 2010; Suzuki et al. 2012; Ting et al. 
2013). Non-human primates represent attractive and relevant animal models for 
preclinical studies of reproductive biology, physiology, ovarian tissue and auto-
transplantation (Stevens 1997; Nyachieo et al. 2013).  
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1.3 HUMAN OVARIAN TISSUE  
The almond- shaped adult human ovary is 3-5 cm in length, 1.5-3 cm in wide and 0.5-
1.5 cm in thickness. A thin layer of dense connective tissue known as the tunica 
albuginea encapsulates the ovary. Immediately beneath this layer lies the stroma that is 
composed of special connective tissue formed by spindle-shaped cells and extracellular 
matrix, supplied by blood vessels. The ovarian follicles are situated at a depth of one to 
two mm from the surface of the ovary, in a layer of stroma, termed cortex (Figure 1).  
 
 
 
 
 
 
 
The cortex contains highly compact connective tissue. Finally, under the cortical layer 
lies the ovarian medulla containing loose connective tissue, blood vessels, lymphatic 
vessels and nerves. The vast majority of the follicles are primordial (88%) whereas 
primary (8%) and secondary (4%) follicles are less frequent (Faddy et al. 1992; Lass et 
al. 1997). Our research group has developed an ovarian tissue culture system in which 
follicular growth in cryopreserved human ovarian tissue has been successfully 
achieved. Ovarian tissue was cultured on diluted extracellular matrix (ECM) i.e., 
Matrigel™ matrix or collagen that maintain the three dimensional organisation of the 
follicle (Scott et al. 2004).  
The developmental stages of the human ovarian follicles are classified by the number 
and shape of granulosa cells around the oocyte. Primordial follicles consist of an oocyte 
Figure 1. The ovarian follicles are located at a depth of 1-2 mm in the ovarian 
cortex (magnification: 100X) 
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surrounded by a single layer of flattened granulosa cells. They have a diameter of about 
30 µm (Figure 2).  
 
 
 
 
 
  
Figure 2. Light micrograph of a primordial follicle (right) and a transitional follicle 
undergoing formation of a primary from a primordial (left) follicle (magnification: 200X) 
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Primary follicles are about 30 - 60 µm in diameter and contain a complete single layer 
of cuboidal granulosa cells. The granulosa cells in the secondary follicles proliferate 
and form multiple cuboidal layers around the oocyte (Figure 3).  
 
 
 
 
 
 
At the secondary stage, the granulosa cells grown in several layers, theca interna and 
theca externa layers have been formed from the outside of the basement membrane 
(Gougeon 1986) and the diameter of the follicle has increased to about 100-200 µm 
(Figure 4).  
 
 
 
Figure 3. Light micrograph of a primary follicle (magnification: 200X) 
 
Figure 4. Light micrograph of a secondary (upper) and several primordial follicles 
(lower) (magnification: 200X) 
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At the next stage, granulosa cells are growing quickly and start to secrete fluid around 
themselves. They soon contain a fluid-filled space called antrum. The follicle is called 
tertiary, or antral and has reached a size of 500 µm in diameter. A fully-grown mature 
follicle containing a large fluid- filled antrum is known as a Graafian follicle. Two 
types of granulosa cells are encountered in these follicles; mural granulosa, which is a 
thin layer around the peripheral of follicle cells, and cumulus cells, surrounding the 
oocyte. By the time of full maturity, the follicle is about 20 mm in diameter (Figure 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 5. Light micrograph of an antral follicle from a 14-year-old girl with 
Turner’s syndrome, (magnification: 100X). Photo by Julius Hreinsson. 
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1.4 FERTILITY PRESERVATION 
1.4.1 Premature ovarian failure 
Female fertility can become negatively affected by a number of conditions, which can 
deplete follicular reserve in the ovary, resulting in premature ovarian failure (POF) 
(Peretz et al. 2001; Larsen et al. 2003; Schmidt et al. 2010). POF is a condition in 
which ovaries stop functioning normally before the age of 40 years and it is estimated 
to affect about 1-2% of all women. Possible causes of POF include genetic defects such 
as Turner’s syndrome, Fragile X syndrome (Beck-Peccoz and Persani 2006) and FSH 
receptor mutations (Aittomaki et al. 1996). An inactivating mutation in the FSH 
receptor prevents the maturation of the follicles beyond the primary stage (Aittomaki et 
al. 1996). There are also many other genetic causes. 
Turner’s syndrome is a chromosomal condition with a total or partial deletion of one of 
the two X chromosomes (45, X). It is a relatively common genetic disorder that affects 
about 1 in 2.500 live born females (Singh and Carr 1966). Turner’s syndrome can cause 
cardiac abnormalities, enlargement of blood vessels and ovarian dysgenesis, i.e., streak 
ovaries with white fibrous stromal tissue. Most girls with this syndrome undergo 
ovarian failure at an early age. Girls with mosaicism may reach spontaneous menarche 
and become pregnant (Hovatta 2012). Other genetic disorders that result in premature 
ovarian failure include fragile X syndrome with a defective gene on the X chromosome 
(Marozzi et al. 2000).  POF develops to 13% of the carriers (Cronister et al. 1991; 
Allingham-Hawkins et al. 1999; Sullivan et al. 2005; Johnston-MacAnanny et al. 
2011). 
Chemotherapy and/or radiotherapy are among the most common causes of premature 
ovarian failure. Since population of survivors is growing constantly, the development 
of methods for fertility preservation before starting cancer treatment has become of 
great importance.  
 
 
  
1.4.2 Toxic impact of chemotherapy and radiotherapy 
 
The risk of premature ovarian failure after gonadotoxic anti-cancer drugs depends on 
the patient’s age at treatment, type of malignancy and treatment protocol (Meirow and 
Nugent 2001; Donnez et al. 2006; Gonzalez et al. 2012). It has been reported that 
women up to 40 years treated with chemotherapeutic drugs have a risk of 61% to 
develop amenorrhea, and the risk increased to 95% when the age of women increased 
from 40 years (Jensen et al. 2011). Meirow also showed that the risk of premature 
ovarian failure was about 42% in women who received alkylating drugs, while no 
significant increased risk of POF was observed among those treated with platinum 
derivatives or plant alkaloids (Meirow 2000). Alkylating agents such as 
cyclophosphamide are highly gonadotoxic since they are not cell cycle- specific and 
affect even other cells in the ovary (Jensen et al. 2011). Although the gonadotoxic 
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effects of cancer treatment are known, the effects of such treatments are not predictable 
since the exact apoptotic pathway involved is not known yet. 
Anticancer drugs affect ovarian function by several ways, such as depletion of the 
primordial follicle pool (burn-out mechanism), ovarian cortical fibrosis and blood 
vessels damage (Meirow 2000; Meirow et al. 2007). 
It has been suggested that anticancer drugs cause follicular depletion by inducing 
apoptosis. Electron microscopic analysis has shown that primordial follicles in human 
ovarian tissue exposed to chemotherapy become surrounded by basal lamina, which 
was abnormally thick. Moreover, the incidence of primordial apoptosis has also been 
demonstrated in human ovarian tissue after transplantation in SCID mice (Oktem and 
Oktay 2007). However, more research is needed to make sure whether the primordial 
follicular apoptosis occurs truly in vivo and if the oocyte or granulosa cells are the main 
targets of apoptosis. Cortical fibrosis and follicular burn-out are other possible 
alternative mechanisms that have been suggested to explain damage follicular reserve 
(Meirow et al. 2010). It is possible that specific developmental stages of follicles are 
more sensitive to toxic effects of chemotherapy than others since there are follicles at 
different developmental stages in the ovary at any time (Morgan et al. 2012). There is 
little data available on this. Decreased numbers of primordial follicles in biopsied 
ovarian tissue from patients treated with chemotherapy have been reported (Meirow et 
al. 2007; Oktem and Oktay 2007; Meirow et al. 2010; Najafi et al. 2011; Das et al. 
2012).  
 
Radiotherapy also causes destruction of the follicular reserve. The extent of harmful 
effects is related on the treatment dose, irradiation field and patient’s age.  
Many types of malignancies in central nervous and hematologic systems are treated 
with high- dose radiation (Meirow et al. 2010). Wherever it is possible, gonads are 
protected from radiation, except if the radiation field overlaps the ovaries, or if total 
body radiation is required (Sanders et al. 1996). In human, the amount of radiation 
required to destroy half of the total number of resting follicles (LD50) is estimated to 2 
Gy (Wallace et al. 2003). Radiation to the pelvis results in ovarian damage, and 
decreases the follicular reserve. It also induces uterine damage that is likely due to 
disruption of uterine blood vessels.  
 
 
1.5 METHODS FOR FERTILITY PRESERVATION 
Currently, several methods exist for female fertility preservation, including ovarian 
protection techniques, embryo cryopreservation, oocyte cryopreservation, ovarian 
tissue banking, followed by auto-transplantation or in vitro culture of follicles within 
ovarian tissue (Hovatta 2005; Silber et al. 2010; Morris and Ryley 2011).   
Ovarian suppression using gonadotrophin- releasing hormone (GnRH) agonists prior to 
and during treatment was claimed to offer some ovarian protection against 
chemotherapy. However, the results have been contradictory and not repeatable. 
(Maltaris et al. 2006; Blumenfeld 2007). 
In 1958, ovarian transposition was described as an ovarian function preserving 
technique (Mc et al. 1958). Surgical ovarian transposition for protecting ovaries from 
injuries following by ionizing radiation to pelvis or abdomen or total body irradiation 
has also been used with some success (Bisharah and Tulandi 2003; Han et al. 2011).  
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The methods to preserve fertility in men with cancer are cryopreservation of 
spermatozoa and cryopreservation of testicular tissue. The latter is the only possible 
method among pre-pubertal boys (Hovatta 2003; Keros et al. 2005). Sperm freezing is 
now a well-established method that has routinely been applied since the 1970’s. 
Intracytoplasmic sperm injection (ICSI) is used for fertilisation of egg with thawed 
sperms and good pregnancy rates can be expected (Hovatta 2003). 
This thesis focuses on developing improved cryopreservation of ovarian tissue for 
fertility preservation in clinical practice. 
 
 
1.5.1 Cryopreservation of embryos 
Embryo cryopreservation is a well -established method that is routinely used in all 
fertility clinics. The first child was born after a pregnancy resulting from a frozen 
embryo transfer in 1984 (Zeilmaker et al. 1984). Children born after frozen embryo 
transfers have not shown any increased risk of birth defects when compared with 
children born after naturally conceived pregnancies (Smitz et al. 2010; Wikland et al. 
2010). Embryo cryopreservation before cancer treatment is suitable for women who 
have partner. However, this procedure needs conventional ovarian stimulation, which 
may require up to two-three weeks.  That is not acceptable for women with highly 
aggressive malignancies such as some leukaemias, which require immediate cancer 
treatment (Dolmans et al. 2005).  
 Moreover, many cancer patients respond poorly to conventional ovarian stimulation, 
which may result in poor quality of collected oocytes during the cycle. An average of 
about 10 oocytes may be obtained although this amount is variable and age dependent. 
Ovarian stimulation procedure may not be an optimal option neither for women with 
hormone-sensitive tumours (e.g. breast and endometrial cancers) (Pena et al. 2002; 
Chen et al. 2003) because of increased oestrogen concentrations in serum during the 
stimulation. In those situations, tamoxifen, a non-steroidal anti-estrogen has been used 
for ovarian stimulation (Oktay et al. 2003). On the other hand, concomitant use of 
aromatase inhibitors with the ovarian stimulation can be safely used (Azim et al. 2007; 
Reddy and Oktay 2012).  
Cryopreservation of embryos is not a feasible option for prepubertal or adolescent girls 
or single women. 
 
 
1.5.2 Cryopreservation of oocytes 
Cryopreservation of mature oocytes after ovarian hyperstimulation cycle involving 
administration of GnRH antagonist, or from natural cycles, is an optional fertility 
preservation method that would abolish the need for a sperm from a partner or donor. 
The world’s first baby using frozen oocytes was born in 1986 (Chen 1986). The live 
birth rate per frozen oocyte when slow freezing was used, was about 2%, which was 
much lower than that achieved using fresh oocytes (Gosden 2005). Matured oocytes are 
more difficult to cryopreserve than embryos. They have a fragile spindle apparatus that 
makes them more sensitive to cryodamage, and they become easily injured by slow 
freezing. In contrast to the poor results and pregnancy rates obtained by slow freezing, 
vitrification of oocytes has resulted in much higher survival rates after warming. It can 
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be expected to give similar clinical outcomes to those obtained by using fresh oocytes 
(Cobo et al. 2008).  Oocyte cryopreservation can be performed for single women, 
couples without sperm available on the day of oocyte pick up and also for already 
menstruating adolescent girls.  Cryopreservation of immature oocytes after in vitro 
maturation (IVM) is also another possible option for fertility preservation. Immature 
oocytes can be obtained from stimulated or non-stimulated cycles (Demirtas et al. 
2008; Huang et al. 2008), and by ovarian tissue biopsy during the ovarian tissue 
cryopreservation procedure (Revel et al. 2003). Maturation of oocytes in vitro followed 
by vitrification offers also an approach for fertility preservation (Demeestere et al. 
2009; Anderson and Wallace 2011) because no hormonal stimulation is needed (Baka 
et al. 1995; Cao et al. 2009; Wang et al. 2012).  
 
 
 
1.5.3 Cryopreservation of ovarian cortical tissue 
As described above, ovarian tissue cryopreservation would benefit prepubertal girls and 
young women who need immediate chemotherapy (Hovatta et al. 1996).  Storing of 
frozen ovarian tissue may also benefit patients with non-malignant diseases such as 
recurrent ovarian endometriosis or recurrent mucinous cysts and other patients 
undergoing prophylactic oophorectomy because of an increased risk of breast cancer 
and ovarian cancer due to an inherited mutation in BRCA1 or BRCA2 gene. The 
procedure does not require ovarian hyperstimulation (Oktay et al. 1998; Donnez et al. 
2000; Gosden 2002; Hovatta 2003; Marhhom and Cohen 2007). Cryopreservation of 
ovarian cortex is the only option for restoring both endocrine function and fertility. To 
date, re-transplantation of frozen-thawed ovarian tissue has resulted in 24 births of 
healthy infants (Roux et al. 2010; Amorim et al. 2012; Greve et al. 2012; Dolmans et 
al. 2013). 
Ovarian biopsy can be performed via laparoscopy or laparotomy immediately before or 
after initiation of cancer therapy. A unilateral or bilateral ovariectomy is performed in 
some rare cases in which no remaining ovarian function can be expected after the 
treatment (pelvic irradiation). Usually, about 25- 50% of the cortical tissue from one 
ovary is removed. This varies depending on the expected ovarian follicle injury after 
exposure to cancer treatment (von Wolff et al. 2009).  The biopsied tissue should be 
large enough and representative as follicle density in the ovary is unevenly distributed 
(Qu et al. 2000; Schmidt et al. 2003). The vast majority of the follicles are located in 
the ovarian cortical tissue. Primordial follicles constitute a majority of 70-90% of all 
follicles in the ovary and a small piece of ovarian tissue may contain hundreds of these 
small follicles (Gougeon 1986; Lass et al. 1997). Hence, they are the main goal of 
cryopreservation programmes. Using cryopreservation, most primordial follicles are 
preserved as they resist cryoinjury due to their small size, low metabolic rate, and lack 
of zona pellucida and cortical granules (Hovatta et al. 1996; Shaw et al. 2000). In 
addition, primordial follicles have more time for repairing sub-lethal injury to 
organelles and other structure during their prolonged growth phase (Picton et al. 2000). 
Considering these advantages discussed above, cryopreservation of ovarian tissue is an 
attractive method for fertility preservation. 
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1.6 TRANSPLANTATION OF OVARIAN TISSUE 
Cryopreserved ovarian tissue can be used by either transplantation or in vitro culture. 
Xenografting is transplantation of ovarian tissue from one species into another. It is an 
excellent tool for studying the survival and developmental potential of follicles in 
ovarian tissue after cryopreservation and thawing. However, xenografting is not 
applicable in clinical practice because of the possible risk for transmission of animal 
pathogens (Kim et al. 2002). Transplantation of ovarian tissue can be done either 
orthotopically or heterotopically. Heterotopic transplantation refers to transplantation of 
a tissue from one place in the body to another place in the same body. Orthotopic 
transplantation refers to re-transplantation of tissue at its origin place. In human, auto-
transplantation of cryopreserved ovarian tissue has been described to restore ovarian 
function and fertility. Heterotopic transplantation of ovarian tissue to the forearm 
(Oktay et al. 2001), or abdomen (Oktay et al. 2004) in a woman has also been resulted 
in regain ovarian function but no pregnancies after embryo transfer have been achieved. 
Orthotopic transplantation of fresh ovarian tissue resulted in the first live primate birth 
in 2004 (Lee et al. 2004). In the same year, the first childbirth following orthotopic 
transplantation of human ovarian cortical tissue was reported (Donnez et al. 2004).  
 Despite these achievements, there is a real concern regarding re-transplantation of 
thawed ovarian tissue because of the possible risk of retransmitting metastatic cells 
(Shaw et al. 1996; Meirow et al. 2008). Therefore, it is important to ensure the safety of 
post-thawed tissue before transplantation by identifying tumour involvement in ovaries 
and detecting the presence of cancer cells in the preserved tissue.  
Before transplantation of ovarian tissue from hematologic cancer patients, minimal 
residual disease must be identified (Meirow et al. 2008). In 2008, chronic myeloid 
leukemia (CML) cells were detected by real-time quantitative polymerase chain 
reaction (RT- qPCR) in post-thawed ovarian tissue. That led to cancellation of re-
transplanting the post-thawed ovarian tissue. RT- qPCR showed to be positive for 
BCR-ABL transcripts (Meirow et al. 2008).  
Recently a Japanese study reported the incidence of ovarian leukemic involvement in 
8.4% of leukemia patients. This study was based on retrospective analysis of 5.571 
autopsy findings of women younger than 40 years (Kyono et al. 2010).  Molecular 
biology has been recently used to detect the presence of leukemic cells in 
cryopreserved ovarian tissue from patients with CML, acute myeloid (AML) and acute 
lymphoblastic leukemia (ALL) (Dolmans et al. 2010; Rosendahl et al. 2010; Dolmans 
et al. 2013; Rosendahl et al. 2013). 
Taking together, ovarian tissue should actively be cryostored for fertility preservation 
but much care should be taken for auto-transplantation of cryopreserved tissue because 
reliable methods to detect the minimal residual disease in grafts are not available yet. 
Among high-risk patients, culture of the ovarian follicles and oocytes to full maturity in 
vitro would be a better option. 
 
1.7 CULTURE OF OVARIAN FOLLICLES 
In vitro maturation (IVM) of oocytes obtained from maturing follicles would be the 
safest method for utilizing cryopreserved ovarian tissue from patients with 
haematological malignancies, which may be transmitted by re-transplantation of the 
tissue (Shaw et al. 1996; Hovatta et al. 1997). Maturation of the follicles to antral stage 
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is a complex procedure that requires understanding of these cells and their requirements 
at different developmental stages. Primordial follicles in newborn mice ovaries have 
been successfully cultured in two steps, become matured and ended in one live birth 
even short-lived (Eppig and O'Brien 1996). In this study, at the first step primordial 
follicles in ovarian tissue were cultured for 8 days. Thereafter, they were enzymatically 
isolated and cultured for additional 14 days. Then the oocytes in oocyte-granulosa 
complexes were removed and become matured by IVM technique. Seven years later, 
the same researchers reported 59 normal pups after improvement of their previous 
culture medium (O'Brien et al. 2003).  
 
Culture of isolated follicles from the stromal tissue has also been studied. Follicles can 
be isolated either mechanically e.g., needle or enzymatically e.g., collagenase. 
However, isolation of human follicles is technically difficult because of the fibrous and 
high density of ovarian stroma. In human, both mechanical and enzymatic isolation 
proved to cause irreversible damages in early antral follicles.  The oocytes were 
expelled from the follicles in culture (Hovatta et al. 1999). In partially isolated follicles, 
the oocytes were also extruded after two weeks of culturing. This suggested that the 
surrounding cells of stroma and theca are important for supporting follicular survival 
and development. 
 Immature oocytes can be aspirated from small antral follicles for clinical in vitro 
maturation (IVM). They can be fertilised, and embryos can be transferred for fertility 
treatment. Many healthy children have been born after IVM treatment (Cha et al. 1991; 
Barnes et al. 1995; Hreinsson et al. 2003). 
Culture of follicles within the ovarian tissue was shown to be an excellent method in 
human (Hovatta et al. 1997; Hovatta et al. 1999).  Both fresh and frozen-thawed 
ovarian tissue was cultured for 21 days (Hovatta et al. 1997). The proportion and 
density of viable follicles in cultured frozen-thawed ovarian tissue was similar to that in 
fresh tissue.  After 10-15 days of culture, two-third of the follicles in the frozen thawed 
tissues were viable. The availability of human ovarian tissue for research has been a 
limiting factor in these studies. Human ovarian tissue could be obtained by donation 
from women undergoing gynaecological surgery or caesarean section (Hovatta et al. 
1997). The culture of human ovarian follicles is still challenging. Our research group 
has studied factors that are involved in human folliculogenesis. Adding of GDF-9 and 
cGMP into the culture increased the viability, recruitment and early growth of ovarian 
follicles (Hreinsson et al. 2002). c-Kit receptor is important in the survival of the 
follicles in the human ovary during the early development. Kit ligand (KL, also known 
by name stem cell factor, SCF) mRNA and c-Kit mRNA and protein are expressed in 
follicles at all developmental stages (Carlsson et al. 2006). In addition, antimüllerian 
hormone (AMH) plays an important role by inhibiting the follicles from entering the 
growing pool (Carlsson et al. 2006).  
We now culture human ovarian tissue pieces and isolate follicles mechanically after 4 
days. Then the follicles are cultured in a medium comprising Dulbecco’s Modified 
Eagle Medium (DMEM- GlutaMax) supplemented with Antibiotic/ Antimycotic 
solution, insulin transferrin selenium (ITS), HSA, FSH, a PTEN -inhibitor (bpVHopic) 
and activin A or GDF-9 for two weeks. The purpose is to isolate cumulus-oocyte 
complex  (COC) and mature the oocyte in vitro in the future (Figure 6). 
 
 
  16 
 
 
 
 
 
  
Figure 6. A tertiary follicle in biopsied human ovarian tissue cultured for 4 days, then partially 
isolated and cultured for further 8 days in activin A and a PTEN inhibitor containing medium. 
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1.8 CRYOBIOLOGY 
To understand the effect of very low temperatures on cells and tissue we have to take 
into account that many structures and processes are temperature dependent. Hence, 
cooling has extremely complex effects that produce conditions over the normal 
physiology. Currently, there are two main methods for cryopreservation of ovarian 
cortical tissue, slow freezing and vitrification. Both methods permit cells to be stored 
indefinitely by using extremely cold temperatures to stop metabolic activities. In both 
procedures, cryoprotective agents are used to prevent cellular damage during the 
freezing process. Once cells are frozen or vitrified, they can be stored by plunging them 
into liquid nitrogen.  
 
 
1.8.1 Freezing injury 
At least 80% of the tissue mass consists of water that freezes when cooled below 0°C. 
Freezing occurs by conversion of water to ice crystals. This results in concentration of 
the dissolved solutes in the remaining liquid phase, and precipitation of the solutes 
exceeded their solubility limit. 
Following the breakthrough articles by Lovelock (1950), it has been concluded that the 
freezing damage is caused either by reduction in temperature or changes in the solution 
composition by freezing, or both (Lovelock 1953; Meryman 1968). 
Cooling and warming rates are two important determinants in survival of cells during 
cryopreservation. In 1963 Mazur discovered the importance of the rate of temperature 
change that controls the movement of water across the cell membrane and hence, 
indirectly, the possible intracellular freezing (Mazur 1963). 
Crystallisation (nucleation) starts when cooling temperature falls below the freezing 
point (0°C) and builds crystals. In addition, the growth of ice crystals is a heat 
generating process, and it tends to increase the temperature of the system to the freezing 
point. The growth of ice crystals is maximal just below the freezing point, so that by 
further cooling, it is arrested. At lower temperature (~ -50°C) the concentration of the 
solution surrounding the cells is changed, which results in increased viscosity of the 
fluid by osmotic gradient. The cells will dehydrate and shrink at a rate depending on the 
rate of ice formation. The rate of temperature changes influences the rate at which 
water moves out of cells (during cooling) or into the cells (during warming). Increased 
viscosity prevents ice crystal formation. Water leaves the cells quickly across the cell 
membranes, and the cytoplasm will not cool below its freezing point. This leads to 
extracellular freezing because all the ice formed is outside the cells. On the other side, 
if the cooling is too fast, sufficient transport of water out of the cells will not be 
possible and the cytoplasm of the cells will freeze. Each cell type has maximal survival 
at a characteristic cooling rate due to the effects of solution and intracellular freezing 
(Mazur 1963). Ice crystals can also be rebuilt during warming. The rate of warming has 
an important effect because very small amounts of intracellular ice crystals are capable 
to grow. Based on the rate of warming, the behaviour of these small ice crystals is 
different. During slow warming, the ice crystals are recrystallized and grow together 
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but during rapid warming there is no efficient time to recrystallize and the ice simply 
will melt (Pegg 2007). 
 
 
1.8.2 Cryoprotection 
Cryoprotection involves addition of cryoprotective agents (CPAs) in solute in order to 
protect the cells/ tissues from cryoinjury during cryopreservation. Addition of CPAs 
produces osmotic dehydration and a diffusion force for solutes. Free diffusion of 
solutes is limited by barriers in the biological system. These barriers can cause transient 
and equilibrium changes in the volumes of the compartments.  These changes can be 
damaging to cells if they are excessive. Therefore, both processes of diffusion and 
osmosis are very important in cryopreservation (Kedem and Katchalsky 1958; Lees et 
al. 1989). 
CPAs reduce the formation of ice crystals by increasing the total concentration of all 
solutes in the system. Hence, some of them must be able to penetrate into the cells and 
have low toxicity. Cryoprotectants must be highly water-soluble, even at low 
temperatures in order to lower the freezing temperature. Glycerol, dimethyl sulphoxide 
(DMSO), 1,2 propanediol (PrOH) and ethylene glycol (EG) are some of the CPAs with 
these properties. 
 
1.8.3 Properties of cryoprotectants 
Cells that undergo cryopreservation are exposed to damage caused by intracellular ice 
crystal formation and build-up extracellular salts in the cells as they dehydrate. 
Cryoprotective agents protect cellular damage during freezing and thawing. They 
dehydrate the cells during freezing by creating osmotic gradients (Shaw et al. 2000). 
When CPAs are added in cryopreservation solution, they create an osmotic gradient 
that causes water moving out of the cells that become shrunken. In addition, CPAs 
function by lowering the freezing points of the extracellular solution. In this manner, 
cells have enough time to become dehydrated before the temperature reaches the 
freezing point of the cytoplasm.  Hence, the main function of CPAs is to avoid 
intracellular ice crystal formation, which is the main cause of damage during freezing 
and thawing processes. The cryoprotective agents penetrate the cell membrane and 
stabilise intracellular proteins during freezing (Hovatta et al. 1996; Picton et al. 2000). 
Newton et al, (Newton et al. 1996) showed that human ovarian tissue frozen without a 
cryoprotectant was composed of only traces of fibrous tissue, confirming that that CPA 
is necessary for survival of follicles after freezing and thawing. 
 
Human ovarian tissue has been cryopreserved using several permeating CPAs such as 
DMSO, PrOH and EG. Two agents, DMSO and PrOH have been compared in 
solutions for cryopreservation of ovarian tissue. There was no significant difference in 
any of those cryoprotectants regarding to morphological changes of the follicles after 
cryopreservation and thawing (Hovatta et al. 1996). Follicles in these frozen- thawed 
tissues were cultured for 24 days and showed a survival rate similar to that in non-
frozen tissue (Hovatta et al. 1997). Live births have been reported after transplantation 
of human ovarian tissue cryopreserved using DMSO and EG (Donnez et al. 2004; 
Andersen et al. 2008). Follicle growth in frozen-thawed human ovarian tissue was 
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shown after transplantation into immunodeficient (SCID) mice.  Ovarian tissues were 
cryopreserved in PrOH using of slow freezing (Van den Broecke et al. 2001). Both 
DMSO and EG have been frequently used in ovarian tissue cryopreservation (Kagawa 
2009). EG is recently used commonly for rapid cooling (vitrification) of human ovarian 
tissue (Huang et al. 2008; Wang et al. 2008; Amorim et al. 2011) since it has a lower 
molecular weight and higher permeability into the cells than DMSO (Bautista and 
Kanagawa 1998; Kuleshova et al. 1999). DMSO is an effective glass former (Fahy et 
al. 2004) that usually is used in combination with another strong glass former such as 
PrOH or poor glass former such as EG, acetamide and formamide (Fahy et al. 2004).  
In cryopreservation of ovarian tissue, a permeating CPA is combined with non-
permeating CPAs such as polymers, sucrose, albumin and serum proteins. The non-
permeating CPAs influence viscosity of freezing solutions and act as osmotic buffers to 
prevent cells from becoming shrunken and swollen during freezing and thawing (Picton 
et al. 2000). Usually sucrose is used at a concentration of 0.1- 0.2 M whilst the 
concentration of used serum and albumin is varying. Our group has showed that human 
serum albumin (HSA) was as efficient as serum when added in respective 
cryoprotectant solutions (Hreinsson et al. 2003). HSA is used in clinical practice 
because the risk of infection is smaller than that with serum. 
 
 
1.8.4 Preservation of cells and tissues 
The basic knowledge about cryobiology has helped researchers to develop effective 
cryopreserving methods for a wide range of cells. It is possible to predict the conditions 
for effective cryopreservation if the characteristics of the cell are known.   
The situation is more difficult for a complex system with a heterogeneous collection of 
cells. Hence, it is necessary to find a technique that can favour the adequate safety of 
survival of the all cell types that are important for tissue function. Moreover, it is 
important to protect extracellular structures from damage and maintain the normal 
interactions between the cells and their attachments to the basement membranes (Pegg 
1987). Extracellular ice remaining in the system can destroy the structure of the tissue. 
(Pegg et al. 1987). The amount of the cryodamage is dependent on where the ice is 
formed.  This location is influenced by the cooling rate used (Hunt et al. 1982; Pegg 
2010). Functional vasculature is very necessary and ruptured vasculature is lethal in 
tissue and organs. Therefore, it is important to avoid this problem by preventing 
freezing or at least reducing the amount of ice crystals in the susceptible locations(Pegg 
2007). 
 
 
 
1.8.5 Slow freezing/ rapid thawing  
Slow freezing has been routinely used for cryopreserving human ovarian tissue since 
1996 (Hovatta et al. 1996). Ovarian tissue is cooled very slowly (2-3 hours) down to  
- 150°C using a programmable freezer, followed by storage in liquid nitrogen (- 196°C) 
and, thawed rapidly in 1 minute from - 196°C to room temperature. Frozen tissue in a 
cryovial is thawed by first keeping in the air for 30 seconds and then put it in a water 
bath (30°C) until the ice melts. The starting temperature for the procedure with PrOH- 
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sucrose is +18°C and for that with DMSO is 0°C. Ovarian tissue is cooled from the 
starting temperature to -8.0°C (for PrOH-sucrose) -7°C (for DMSO) and at a rate of 2.0 
°C/min. Ice crystal induction outside the tissue is performed with pre-cooled forceps, 
by touching the container after a 10 min holding time. It is then cooled to -30°C at a 
rate of 0.3°C/min and plunged into liquid nitrogen during a free fall from -35°C 
(50°C/min to - 150°C for PrOH-sucrose and 10°C/min to - 150°C for DMSO) (Hovatta 
2005). 
Ovarian tissue is first equilibrated in a cryoprotectant solution to allow the CPA to 
penetrate into the cells. The optimal penetration rate for DMSO was achieved at 4°C 
for 30 min (Newton et al. 1998). The equilibration time used for PrOH has varied 
between 15-90 min at room temperature. The longer incubation time (90min) showed 
the best ultrastructural morphology for both stroma cells and follicles (Hovatta et al. 
1996; Hovatta et al. 1997).  
 
1.8.6  Vitrification/ warming 
Vitrification is another cryopreservation technique. It is usually achieved by rapid 
cooling of a liquid that contains a high concentration of a cryoprotectant. In 
vitrification, the cooling induces formation of glass-like substance (glass=vitrum) 
instead of freezing into solid ice with crystals. Successful vitrification requires both 
high concentrations of cryoprotectants and high cooling rates, which can be achieved 
by plunging the tissue directly into liquid nitrogen. A combination of cryoprotectants 
including other permeating cryoprotectants avoids the toxicity of each individual CPA. 
The permeability of a combination of cryoprotectants is higher than that of each 
individual one (Vicente and Garcia-Ximenez 1994). Furthermore, a stepwise exposure 
of cells to precooled concentrated vitrification solution reduces the suspected toxicity of 
CPAs (Liebermann et al. 2002; Hovatta 2005). Moreover, addition of non-permeating 
cryoprotectants influence the viscosity of the vitrification solution and promote glass 
formation, which results in reduction of toxicity since they allow addition of a lower 
concentration of permeating cryoprotectants without compromising vitrification 
properties (Bautista and Kanagawa 1998; Liebermann et al. 2002; Pegg 2005). The 
toxicity of CPAs can also be reduced by adding a non-permeating polymers such as 
Ficoll, dextran, polyethylene glycol (PEG) and polyvinylpyrrolidone (PVP) (Fahy et al. 
1984). These polymers reduce the mechanical stress that occurs during 
cryopreservation and may partially cause the cryoinjury in the cells. Polymers influence 
the viscosity of the vitrification solution and lower the concentrations of the 
cryoprotectants, which in turn reduces the toxicity of the cryoprotectant solution (Shaw 
et al. 1997). 
Successful results from vitrified human oocytes and blastocysts have been achieved. 
The complex and dense human ovarian tissue is much more difficult to vitrify. For 
vitrification of ovarian tissue, several permeating CPAs such as, DMSO, EG, PrOH, 
glycerol, acetamid and formamide have been used. EG with low toxicity, has been 
commonly used as a cryoprotectant for vitrification of human ovarian tissue (Huang et 
al. 2008; Wang et al. 2008; Amorim et al. 2011).  
 
 
1.8.6.1 Slow freezing and vitrification of human oocytes  
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Oocytes can be cryopreserved by two methods, slow freezing (Chen 1986)or 
vitrification (Kuleshova et al. 1999). When slow freezing and vitrification were 
compared, vitrified oocytes showed better survival rates than those frozen by slow 
freezing (Monzo et al. 2012). Several studies have reported low survival and 
implantation rates with a few pregnancies, following slow freezing of mature (Porcu et 
al. 1997; Fabbri et al. 2001; Borini et al. 2006; Levi Setti et al. 2006) (Konc et al. 
2008) and immature oocytes (Cha et al. 1991; Trounson et al. 1994; Tucker et al. 
1998). Slow freezing can cause modification of the membrane structure and affect 
oocyte microtubules, cytoskeletal organization and the zona pellucida (Ghetler et al. 
2005; Bromfield et al. 2009). Based on poor survival rates, cryopreservation of oocytes 
by slow freezing has not been extensively applied.  
Vitrification does not affect the physiology of oocytes as extensively as slow freezing. 
A higher survival rate has been achieved after warming. Hence, it has recently been 
used as an alternative method for cryopreserving oocyte in several laboratories, 
(Lucena et al. 2006; Antinori et al. 2007; Cobo and Diaz 2011). In a study on 936 
children born after oocyte cryopreservation, Noyes et al. reported that there was no 
higher incidence of congenital anomalies when compared with naturally conceived 
newborn babies. The study included 532 live born children resulting from slowly 
frozen oocytes, 392 from vitrified oocytes and 12 from a combination of both 
cryopreservation methods (Noyes et al. 2009). 
 
 
1.8.6.2 Slow freezing and vitrification of human ovarian tissue  
 
Cryopreservation of human ovarian cortical tissue is challenging because it contains 
many different cell types such as stromal cells, follicles with oocytes that are 
surrounded by granulosa cells and blood vessels. These cells have different 
requirements for optimal survival during cryopreserving and thawing processes 
(Hovatta 2005). Cryopreservation of human ovarian tissue using slow freezing is a 
method with remaining follicular function after thawing (Hovatta et al. 1996; Newton 
et al. 1996).  Cryoprotectants such as DMSO and PrOH with sucrose are widely used in 
slow freezing protocols that result in high survival rates of follicles. Frozen-thawed 
follicles in cortical slices survived two weeks of culture and remained functional after 
transplantation to SCID mice (Hovatta et al. 1997; Van den Broecke et al. 2001). After 
xeno-grafting, mature oocytes were obtained (Gook et al. 2005). Despite these 
achievements, cryopreservation of ovarian tissue by slow freezing is limited by 
relatively poor survival of the stroma (Gook et al. 2000; Hreinsson et al. 2003). The 
stroma and the blood vessels play a critical role in the development of follicles and 
restoration of gonadal function after transplantation. Hence, a proper preservation of 
stroma and blood vessels is basically important (Woodruff and Shea 2007).  
 
Therefore, we have developed vitrification protocols for human ovarian tissue to 
improve the viability of the stroma in addition to the follicles and oocytes. Vitrification 
of human ovarian tissue has been investigated during the recent 10 years. Many 
researchers have studied various vitrification solutions and carrier systems and 
evaluated the effect of different vitrification protocols on ovarian tissue (Isachenko et 
al. 2007; Huang et al. 2008; Wang et al. 2008; Isachenko et al. 2010; Xiao et al. 2010). 
Many of the conclusions from these early diverse studies have been contradictory. 
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There are limited data from studies in which vitrification and slow freezing of human 
ovarian tissue have been compared (Gandolfi et al. 2006; Isachenko et al. 2007). 
Vitrification is not one single method, and conditions can vary widely. The different 
results reported may due to differences in the procedures such as cryoprotectant 
composition and concentration, exposure times to cryoprotectants, cooling rates, carrier 
systems and sizes of fragments. Many studies support vitrification of human ovarian 
tissue by reporting results on well- preserved ultrastructure of follicles and stroma 
tissue (Wang et al. 2008; Kagawa et al. 2009; Xiao et al. 2010). Therefore, vitrification 
seems to be preferable for preserving more complex and heterogeneous tissues such as 
ovarian cortical tissue. The main differences between slow freezing and vitrification are 
demonstrated in Table 1. 
 
 
 
 
 
Parameters 
 
Vitrification Slow freezing 
Direct contact with liquid nitrogen 
 
 
Ice crystal formation 
 
Cooling rate (ºC/min) 
 
Exposure to cryoprotectant  
 
Concentration of cryoprotectant 
 
Time consuming (for one run) 
 
Cost 
 
Special equipment required 
 
Yes  
(Before our studies) 
 
No 
 
15.000- 30.000 
 
Yes 
 
High (>40%) 
 
Minutes 
 
Inexpensive 
 
No 
No 
 
 
Yes 
 
0.15- 0.30 
 
Yes 
 
Low (10-15%) 
 
Hours 
 
Expensive 
 
Yes 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Comparison of cryopreservation methods for human ovarian tissue 
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1.9 THE SWEDISH TISSUE LAW AND THE EUROPEAN UNION TISSUES 
AND CELLS DIRECTIVE 
The European Union Tissues and Cells Directive (EUTCD) establishes the 
regulation for cells and tissues used clinically in Europe. The Directives set a standard 
for handling, application and traceability of the cells and tissues from a donor to a 
patient. The EUTCD includes three directives, the directive (2004/23/EC), which 
contains the framework legislation, and the two technical directives  (2006/17/EC and 
2006/86/EC). The Swedish Tissue Law 2008:286 is built upon the EU Directives and 
consists of quality and safety standards for processing   tissues and cells for clinical use 
and for manufacture of medical products for humans. (www.vavnad.se). 
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3 AIMS OF THE STUDIES 
 
 
General aim: 
 
The overall aim of the thesis was to improve the cryopreservation of human ovarian 
tissue by developing a clinical grade vitrification. 
 
 
 
Specific aims listed according to each article: 
 
1. To improve the method of cryopreservation of ovarian tissue  
 
2. To develop a vitrification method for human ovarian tissue that could be 
applied in a clinical setting. 
 
3. To evaluate the incidence of apoptosis after vitrification, by using TUNEL 
assay and DNA laddering.  
 
4. To improve and simplify the cryopreservation procedure by using a solution 
that only contains one permeating cryoprotectant, EG, in addition to the non-
permeable ones, Ficoll and sucrose. 
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4 MATERIALS AND METHODS 
1.10 ETHICS STATEMENT 
Ethics approvals were obtained for all the studies presented in this thesis from the 
Regional Ethics Board in Stockholm, project number 2005/589-31. All of the tissue 
biopsies used in articles I, II, III and IV were collected at the Karolinska University 
Hospital Huddinge, while for article III collection of biopsies were performed at the 
Karolinska University Hospital Huddinge and at the Tarbiat Modares University 
Hospital, Tehran. The Iranian ethics approval was obtained from the Ethics Committee 
of Tarbiat Modares University (ref. 5274856; 7 December 2010). 
 
 
1.11 HUMAN OVARIAN TISSUES FOR RESEARCH 
The methods are described in a general manner in this section, for further details please 
see the individual articles. 
 
Small pieces of ovarian cortical tissue (diameter <5 mm) were obtained by biopsy from 
59 women 22-43 (mean 33) years of age. All women underwent elective Caesarean 
section and had given informed consent for participation in all studies.  
Ovarian tissue was collected and transported directly to the laboratory in sterile 50 ml 
Falcon tubes (Becton Dickinson, Bedford MA, USA) containing 20-50 ml Flushing 
medium (Medicult Jyllinge, Denmark). The tissue was transferred to a culture dish 
(Becton Dickinson, Bedford MA, USA) containing flushing medium and most of the 
medullar tissue was removed. The cortical ovarian tissue was then cut into pieces of 
about 1-1.5 mm3 with scalpel, keeping the tissue immersed in collection medium while 
working under a stereomicroscope.  
Within the individual studies, each biopsy sample was equally divided into groups and 
exposed to the different treatments. 
 
Article I 
Cortical ovarian tissue was cut into small pieces of approximately 1-2 x 5-8 mm3. Two 
small tissue pieces were taken as non-vitrified controls and fixed for light microscopy 
(LM) and transmission electron microscopic (TEM) evaluation. The remaining pieces 
of the tissue were frozen either by using slow freezing or vitrification. After warming, 
two pieces were fixed for LM and TEM analyses. The cortical tissue was stored in 
liquid nitrogen for at least one week before thawing/warming and culturing. 
 
Article II 
Small cortical ovarian tissue pieces 1-1.5 mm3 were taken for both non-vitrified 
controls and for vitrification. Two control pieces, and pieces from the vitrified tissue 
were taken for LM and TEM analysis. Tissue was cultured for 24h either before or after 
thawing. 
 
Article III and IV 
 
Ovarian tissue 1-1.5 mm3 was vitrified using two vitrification solutions. Samples from 
non-vitrified and warmed/ vitrified tissue were fixed for LM and TEM evaluation, 
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before and after culture. Table 2 summarize the cryopreservation methods used in the 
four articles presented in the thesis.  
 
 
 
 
 
 
 
1.12 CRYOPRESERVATION AND THAWING OF OVARIAN TISSUE 
(ARTICLE I) 
After preparation of ovarian tissue, the tissue pieces were equilibrated with 
cryoprotectants and cryopreserved according to either the method using PrOH and 
sucrose as cryoprotectants for cryopreservation of ovarian tissue described by Hovatta 
et al. (Hovatta et al. 1996) or using EG and sucrose as cryoprotectants. 
 
Slow freezing (PrOH and sucrose) 
The cryopreservation medium was commercially obtained (Freezing Kit I, Vitrolife, 
Gothenburg, Sweden). It consisted of three solutions. The basic solution was 
Phosphate- buffered Saline (PBS) supplemented with human serum albumin (HSA). 
The first cryo- solution contained 1.5M PrOH as a permeating cryoprotectant and the 
second one contained 1.5M PrOH and 0.1M sucrose as a non-permeating 
cryoprotectant. The incubation times were 5, 10 and 15 min in each cryo-solution. All 
steps were carried out at room temperature. The tissue was transferred into a 1.8 ml 
Nunc cryovial (Nunclon, Roskilde, Denmark) containing 1ml of the third cryo-solution 
and placed in a programmable freezer (CryoLogic, Australia). Then samples were 
cooled from room temperature to -6.5 °C at a rate of -2.0 °C/min. Seeding was 
performed by using a forceps, precooled in liquid nitrogen during 10 min of holding. 
Then samples were cooled to -35 °C at a rate of 0.3°C/min and plunged in liquid 
nitrogen during a free fall from -35°C to -196°C.  
 
Slow freezing (EG and sucrose) 
The tissue was rinsed several times in an isotonic saline solution, and then it was 
transferred to 1 ml of PBS (Invitrogen, Scotland) containing 1.5 M EG and 0.1 M 
sucrose (Sigma-Aldrich, Sweden) and HSA (10mg/ml) (Vitrolife, Gothenburg, 
Freezing methods used 
 
Article I Article II Article III Article IV 
Slow freezing using EG 
 
Yes No No No 
Slow freezing using PrOH 
 
Yes No No No 
Vitrification using  
DMSO, PrOH, EG 
 
Yes Yes Yes Yes 
Vitrification using only  
EG   
 
No No Yes Yes 
Table 2. Freezing methods used in the four studies  
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Sweden) for 30 min at 4 °C. Then the piece was placed into 1.8 ml cryovials. The 
samples were cryopreserved at similar rates as described above but the starting 
temperature was 4 °C. 
 
Thawing after slow freezing 
For PrOH and EG, thawing was performed at room temperature. The cryovials were 
removed from the liquid nitrogen, air-thawed for 30s and plunged into a water bath 
(37°C) until the ice was melted. 
PrOH thawing procedure 
 The tissues were thawed using thawing solutions, Cryo-PBS, containing HSA (Thaw 
Kit 1, Vitrolife). The tissue piece was immediately transferred into thawing solutions 
with 1.0M PrOH and 0.2M sucrose. After five min they were transferred into medium 
with 0.5 M PrOH and 0.2M sucrose and after another five min into medium with 
0.2M sucrose for 10 min.  
EG thawing procedure 
After thawing, tissues were rinsed in a medium containing PBS, 0.75 M EG and 0.25 
M sucrose for 10 min. Then they were transferred to a medium containing PBS and 
0.25 M sucrose and incubated for 10 min, and transferred to another medium 
containing PBS and again incubated for 10 min. 
 
 
1.13 VITRIFICATION AND WARMING OF OVARIAN TISSUE (ARTICLES 
I, II, III & IV) 
 
Vitrification procedure: Solution containing a combination of DMSO, EG, PrOH 
and PVP (Articles I, II, III, IV) 
 
In our vitrification procedure, for ovarian tissue samples we used solutions with 
increasing concentrations of dimethyl sulphoxide (DMSO) (Sigma-Aldrich, Sweden), 
1,2- propanediol (PrOH) and ethylene glycol (EG) (Invitrogen, Corporation, Scotland, 
UK) supplemented with 10 mg/ml HSA  (Vitrolife). After washing for 5 min in Hank’s 
balanced salt solution (HBSS) with 10 mg/ml HSA, cortical tissue pieces were 
incubated sequentially in vitrification solutions (VS) including VS1 (0.35 M DMSO, 
0.38 M PrOH, 0.38 M EG), VS2 (0.70 M DMSO, 0.75 M PrOH, 0.75 M EG) and VS3 
(1.4M DMSO, 1.5 M PrOH, 1.5 M EG), at 2.5, 5 and 10% of each cryoprotectant, 
respectively. The third solution was also supplemented with (10%w/v) polyvinyl 
pyrrolidon (PVP, Sigma- Aldrich, Sweden). The first and second incubation steps were 
performed at room temperature. The third one contained higher concentration of 
cryoprotectants at 4°C.  
In article I, two incubation times of 5 min (Vit5) and 10 min (Vit 10) were tested in 
each solution. In articles II, II and IV the stepwise incubation times were 5 min in VS1 
and 10 min in VS2, VS3 and VS4, respectively. 
 
In article I, an open system was used to vitrify cortical tissue.  Pieces of ovarian tissue 
were put in a 0.5 ml insemination cryostraws (IMV- Technologies, L ´Aigle, France), 
which were hand-cut by scalpel. Afterwards, the cryostraw with tissue was plunged 
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into liquid nitrogen and placed in a pre-cooled 5.0 ml Nunc cryovial (Nunclon, 
Roskilde, Denmark), the cap lid closed and stored in liquid nitrogen. 
 
In articles II and IV, a closed system was utilised to vitrify cortical tissue. In article III, 
an open vitrification system was used. The tissue piece was transferred into a pre-
cooled 1.8 ml NUNC cryotube (Nunclon, Roskilde, Denmark), with a minimum of the 
vitrification medium using a small spoon for not to squeeze the tissue. The cryotube 
was tightly closed and plunged directly into liquid nitrogen. Tissue preparation and 
banking was carried out in a closed sterile, system with traceable components, in a 
controlled and defined sterile environment. 
 
Warming 
For warming, the open straw (Article I) was removed from the cryotube and directly 
plunged into the first pre-warmed, 37°C, solution, which consisted of HBSS and 10 
mg/ml HSA supplemented with 0.5 M sucrose, until the tissue sample was rolled out 
from the straw into a dish. In articles II, III and IV, the cryovial was removed from 
liquid nitrogen, kept at room temperature for 30 sec and then immersed in a 37°C water 
bath until the ice melted. After warming, the cortical tissue was transferred into the first 
pre-warmed, 37°C, solution for about two min. Then the tissue piece (Articles I, II, III 
and IV) was incubated in the warming solutions that consisted of HBSS/ HSA 
supplemented with 0.25 and 0.125 M sucrose, respectively. The fourth solution 
consisted of HBSS supplemented with (10 mg/ml) HSA. The incubation time for the 
last three solutions was five min in each. All steps were performed at room 
temperature.  
 
 
Vitrification procedure: A solution containing 40% EG and Ficoll (Article III) 
 
Ovarian cortical tissue was equilibrated in one incubation step in solution containing 
40% EG (v/v), 30% Ficoll 70 (w/v) and 1 M sucrose supplemented with bovine serum 
albumin (BSA) for 5 minutes at room temperature. The tissue pieces were transferred 
to a cryotube with a minimal volume of the vitrification medium and plunged into 
liquid nitrogen. The vitrified tissues were stored in a liquid nitrogen storage tank until 
further experiment. 
 
 
Vitrification procedure: A solution containing 40% EG and Ficoll (Article IV) 
 
The vitrification procedure was as described previously in article III, but in this study 
(Article IV) we used human serum albumin (HSA) instead of BSA. The aim of this 
study was to perform a vitrification procedure for human ovarian tissue that could be 
carried out in a clinical setting. Hence, HSA instead of BSA was used in vitrification 
solution. Moreover, after vitrification, the tissues were stored in the vapour-phase 
nitrogen storage freezer (Air liquid- DMC, Espace, France) to avoid possible microbial 
contamination by liquid nitrogen. The tissue preparation, the vitrification, banking and 
warming procedures were carried out in a closed sterile and traceable system, in a 
controlled and defined sterile environment. Hence, the system is compatible with 
European tissue directive and the Swedish Tissue Law. 
To carry out the vitrification itself, tissue pieces were transferred with a minimum 
volume of the vitrification medium into pre-cooled NUNC cryotube containing an 
internal thread cap, to make it leak proof. The cryotube was immersed into liquid 
nitrogen leaving the screw cap above the surface to avoid leaking.  
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After vitrification and culture, the morphology of the follicles was analysed by using 
light (LM) and electron microscopy (TEM). The ultrastructural changes of the oocytes, 
granulosa cells and stromal cells after vitrification and culture were analysed by using a 
scoring system. Two different investigators judged the morphology blind from each 
other’s results. In the oocyte, the appearance of the nuclear membrane integrity, the 
contents and density of the cytoplasm, microvilli and attachment to the granulosa cells 
were evaluated. In the granulosa cells the chromatin, the density and appearance of the 
cytoplasm, mitochondria and other cellular components in the cytoplasm, and the 
contact to the basement membrane were evaluated. In the stroma, morphology of the 
fibroblasts, the cytoplasm, nuclear contents and collagen matrix were evaluated. The 
maximum scores for the oocytes were three, granulosa cells two and stroma, one 
respectively. A highest score of 1.0 (100%) was given to perfectly preserved cells. The 
final score reflected the preservation of the tissue after using different vitrification 
methods. 
 
Warming (Articles III and IV) 
The warming procedure was similar to that in the second vitrification article. After 
warming, the vitrified tissue pieces were transferred into two warming solutions with 
decreasing concentrations of sucrose (1 and 0,5M) for 5 min in each and at room 
temperature.  
 
1.14 TOXICITY TESTING (ARTICLE III) 
The toxicity of vitrification solutions was tested by subjecting pieces of ovarian tissue 
to the solutions for the two vitrification procedures. All dehydrating and rehydrating 
steps were carried out except plunging into liquid nitrogen. The ovarian tissues were 
fixed in Bouin’s solution for light microscopic analysis.  
 
 
 
1.15 TISSUE CULTURE (ARTICLES I, II, III & IV) 
We evaluated the viability of follicles in the tissue after 24 h culture.  
After thawing all samples (non-vitrified and vitrified) were cultured on 24- well plates 
in humidified air with 5% CO2 at 37°C for 24 hours.  
In article I, the wells contained MilliCell culture inserts (MilliCell, Sigma-Aldrich, 
Stockholm, Sweden) which were coated with 100 µl pre-diluted Matrigel extracellular 
matrix (Becton Dickinson, Stockholm, Sweden) to support tissue growth (Hovatta et al. 
1997). The contents of culture media in all four studies are summarized in the Table 3. 
The details are described in the individual articles. 
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 Culture medium 
Article I α – minimum essential medium (α – MEM), Antibiotic/ Antimycotic 
solution (50 IU/ml, Invitrogen Inc), insulin transferrin selenium (ITS, 10 
µg/ml) (Gibco Invitrogen, Sweden), 10% HSA (Vitrolife,Göteborg, 
Sweden),0.5 IU/ml FSH (Gonal-F; Serono Nordic, Sweden) and 8-
bromo-cGMP (Sigma- Aldrich, 1.1 mg/ml(Scott et al. 2004). 
 
Article II McCoy’s 5a medium with bicarbonate supplemented with HEPES (20 
mM), L-glutamine (3mM), penicillin (100 IU/ml), streptomycin (0.1 
mg/ml), transferring (2.5 µg/ml), selenium (4 ng/ml), insulin (10 ng/ml), 
0.1% HSA and FSH (1ng/ml) all obtain from Sigma - Aldrich, Sweden 
(Telfer et al 2008). 
 
Article III α – MEM, 100 µg/ml penicillin and 50 µg/ml streptomycin, 1 % ITS, 5% 
fetal bovine serum, 100 ml/m recombinant FSH (Gonal-F; Serono), 20 
ng/ml murine recombinant epidermal growth factor (Sigma- Aldrich, 
Germany). 
 
Article IV McCoy’s 5a medium with bicarbonate supplemented with HEPES (20 
mM), L-glutamine (3mM), 0.5% antibiotic/antimycotic solution (50 
IU/ml), insulin transferrin selenium (ITS, 10 µg/ml), 10% HSA and 0.5 
IU/ml FSH (Gonal F, Serono, Sweden). 
 
 
  
Table 3: A summary of the contents of culture media in all four studies  
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1.16 LIGHT MICROSCOPY (ARTICLES I, II, III & IV) 
Ovarian tissue pieces were fixed in Bouin’s solution for 24 hrs at 2-8°C and then 
dehydrated starting in 70% ethanol. The fixed tissues were embedded in paraffin and 
cut in serial sections of 4µm thickness. Every 11th section of each tissue piece was 
mounted on glass slides and stained with haematoxylin- eosin. To prevent double 
counting, each follicle was followed through neighbouring sections and counted only 
once. Analysing adjacent sections confirmed the status of the follicle. Follicles were 
counted and their developmental stages were classified as defined by Gougeon 
(Gougeon 1986) Briefly, follicles were defined as primordial if they contained only a 
single layer of flat granulosa cells and those containing a complete single layer of 
cuboidal granulosa cells were classified as primary follicles and follicles surrounded by 
two complete layers of cuboidal granulosa cells identified as secondary follicles. 
Atretic follicles were defined as those containing an oocyte with eosinophilic 
cytoplasm, contraction and clumping of the chromatin material and pyknotic granulosa 
cells.  A digital image analysis system (Infinity Analyze Imaging Software from 
Lumenera Corporation) connected to an inverted microscope (Nikon, Tekno Optik, 
Stockholm, Sweden) was used to measure the area of the pieces. The volume was 
calculated by multiplying the area of the tissue piece by the known thickness of 4µm. 
 
 
1.17  TRANSMISSION ELECTRON MICROSCOPY (ARTICLES I, II, III & 
IV) 
Tissue specimens taken for TEM were fixed in 2% glutaraldehyde and 0.5% 
paraformaldehyde in 0.1%mol/ml sodium cacodylate buffer and 0.1 mol/ml sucrose pH 
7.4 at room temperature for 2 h and post- fixed in 1% osmium tetroxide. After 
dehydration, the specimens were embedded in LX-112 (Ladd Research Industries Inc., 
Burlington, VT, USA). Thereafter, the samples were cut into about 0.5 µm sections, 
stained with toluidine blue and observed in light microscopy for selecting sections with 
follicles for further examination. Sections were cut into about 50 nm and stained with 
alcoholic uranyl acetate.  The ultra-thin sections were examined using a transmission 
electron microscope (Tecnai, Fei, Eindhoven, and The Netherlands).  Digital images 
were taken at magnifications of x 1250 to x 30 000 using Megaview III camera. 
In all studies, the ultra structural changes in both fresh and cryopreserved ovarian tissue 
were analysed. The structures of oocytes, granulosa cells and stromal cells were 
evaluated separately. The investigators were blinded to the experimental background of 
the specimens. In the oocytes, the integrity of nuclear organelles, the membranes, 
cristae of the mitochondria and their density, the density of the cytoplasm, the content 
of membrane vesicles and attachment to the granulosa cells were evaluated.  The same 
parameters were judged in granulosa cells. The attachment between granulosa cells and 
the attachment to the basement membrane were also evaluated.  
Follicles without any damaged structures in the oocytes and granulosa cells were 
classified as intact whereas those with slight but non-lethal changes were considered as 
influenced. A cell with collapsed and/ or nuclear or plasma membrane disrupted was 
regarded as degenerated. 
 In study IV, a scoring system was performed. The maximum scores for the oocytes 
were three, granulosa cells two and stroma, one respectively. Each individual cell type 
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was given a final score (ratio) by dividing the total number of score gained by 
evaluation to the maximum possible score. A highest score of 1.0 (100%) was given to 
perfectly preserved cells. The final score reflected the preservation of the tissue after 
using different vitrification methods. 
 
 
1.18 IMMUNOHISTOCHEMISTRY (IHC) (ARTICLE IV) 
The occurrence of apoptosis in follicles and stroma in fresh and vitrified tissue was 
assessed by immunohistochemistry for active caspase-3.  
The presence of the active caspase-3 was evaluated by immunohistochemistry using a 
monoclonal antibody against human caspase-3 (Cleaved Caspase-3 (Asp175) (5A1) 
Rabbit mAb, Cell signaling technology). Primary antibody, Cleaved Caspase-3 
(Asp175) (5A1) Rabbit mAb)  (Catalogue no. 9664, Cell Signaling Technology Inc, 
Danvers, Massachusetts, USA) and Polyclonal Goat Anti-Rabbit Immunoglobulins/ 
Biotinylated (Code No. E 0432, DakoCytomation, Denmark) were used. For negative 
controls we used tris-buffered saline instead of primary antibody.  For positive and 
negative control tissue, mouse ovarian tissue was used. 
The immunostaining was performed on two slides, from the three different groups, 
before culture (fresh, vitrified using DMSO, PrOH and EG, and vitrified using only 
EG) (three patients from each group). 
 
 
1.19 TUNEL ASSAY (ARTICLE III) 
After deparaffinization and rehydration, sections were stained to detect DNA fragments 
from apoptotic cells by terminal deoxynucleotidyl transferase- mediated dUTP nick- 
end labelling (TUNEL kit; In situ Cell Death Detection, Roche, Germany). The 
apoptotic signal was recorded as positive when green staining of the nucleus was 
apparent or negative when the nucleus stained red. The test was performed according to 
the manufacturer’s instructions. Ten sections per sample were randomly selected and 
examined by using a fluorescence microscope (Axiophot; Zeiss, Germany). For a 
positive control, dexamethasone- treated mouse thymus was used (Mazoochi et al. 
2008).  
 
 
1.20 DNA LADDERING (ARTICLE III) 
Detection of DNA fragments in apoptotic cells was evaluated using DNA laddering kit 
purchased commercially  (Apoptotic DNA Ladder Kit 1835246; Roche, Germany). The 
test was performed according to the instruction from the manufacture. The DNA 
content was determined spectrophotometrically loaded in 1% agar gel. For a positive 
control, dexamethasone- treated mouse thymus was used (Mazoochi et al. 2008).   
 
 
1.21 STATISTICAL ANALYSIS 
Article I 
Chi-square test for independence with exact p- values was used to assess if the degree 
of follicle viability in LM evaluation was associated with different cryopreservation 
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protocols or fresh control. Pairwise comparisons between protocols were performed by 
Fisher’s exact test. Similar statistical analysis was performed for TEM evaluation of 
oocytes, granulosa cells and stroma. Kruskal- Wallis analysis of variance was used for 
difference in viability of stroma between the cryopreservation protocols. Pairwise 
comparisons between protocols were also performed. P- value was adjusted according 
to the Bonferroni procedure for multiple tests of significance. P<0.05 was considered 
statistically significant. 
Article III 
The Mann- Whitney U-test was used to test differences between groups regarding 
proportions of the developmental stage of the follicles. P<0.05 was considered 
statistically significant. 
Article IV 
The Friedman ANOVA test was used to test the rate of follicular viability in LM 
evaluation when tissues were vitrified or not. The Friedman ANOVA test was also 
performed for TEM evaluation of oocytes, granulosa cells and stroma. Pairwise 
comparisons between protocols were performed in both LM and TEM evaluations. 
P=0.03 in LM evaluation and p=0.02 in TEM evaluation were considered statistically 
significant. 
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5 RESULTS  
1.22 ARTICLE I 
In article I, we carried out the first systematic comparison of slow freezing and 
vitrification of human ovarian cortical tissue. The cryopreservation solutions used in 
slow freezing were PrOH- sucrose and EG- sucrose, and for vitrification it was a 
combination of DMSO, PrOH, EG and PVP with two different incubation times of 5 
min (Vit5) or 10 min (Vit10). The results showed similar and well-preserved 
morphology in follicles within tissues cryopreserved either by slow freezing or 
vitrification. Electron microscopic analysis revealed that the ovarian stroma was better 
preserved in vitrified tissue than that frozen by slow freezing.  
 
A total of 354 follicles was analysed by LM in fresh, slowly frozen and vitrified tissue. 
Of these follicles, 110 (31%) were primordial, 214 (60%) primary, 28 (8%) secondary 
and 2 (1%) atretic follicles. Most follicles were at primordial or primary stage and in all 
samples. Microscopic analysis of hematoxylin-eosin stained sections did not show any 
differences in the structures of follicles frozen after using different protocols. The 
structure of ovarian stroma was impaired in most samples that had been frozen slowly. 
When the stromal structure in slowly frozen tissue was compared to that in fresh tissue, 
there were higher numbers of necrotic stromal cells with pyknotic nuclei and empty 
spaces in the extracellular matrix with disorganized collagen fibres. The quality of the 
stroma in vitrified tissues was as good as that in fresh tissue. The cryo-changes in 
stroma in all cryopreserved ovarian tissue were evaluated by using high power field (n= 
18/ block and treatment). Most stromal cells (98%) in the fresh tissue had intact nuclei. 
There was significantly higher proportion of intact stromal cells in all vitrified tissue 
samples than was found in the slowly frozen samples using either PrOH or EG.  
 
A total of 62 follicles and 633 granulosa cells was analysed by TEM. Fifty-five oocytes 
in these follicles were analysed. Of these oocytes, 14 were in fresh, ten in PrOH, six in 
EG, 19 in Vit5 and six in Vit10 groups. In those sections in which the oocyte was not 
visible, only granulosa cells were analysed. 
The ultrastructure of the oocytes did not vary between groups in any of the tissues.  
The nuclei in almost all samples showed a prominent nucleolus with normally 
distributed euchromatin and heterochromatin.  In the majority of the follicles subjected 
to the different cryopreservation methods, the inner and outer nuclear membranes were 
clearly seen. The nuclear membrane of some oocytes in tissue samples cryopreserved 
using slow freezing with EG was not well preserved. The nuclei and the cytoplasm of 
the oocytes in the cryopreserved tissue that had been frozen slowly using EG were 
blurred after obvious cryoinjury. In tissue samples slowly frozen with EG, the main 
sign of cryoinjury was the increased vacuolization in the cytoplasm and disruption of 
the contact between the oocytes and the granulosa cells. The mitochondria were not 
well preserved in any of the tissue samples cryopreserved using slow freezing.  
In the vitrified tissue samples, the mitochondria with clearly visible cristae showed 
highly organized structure and well preserved membranes. There were no significant 
differences in the viability of the oocytes between any of the studied groups. 
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The ultrastructure of the granulosa cells in all the studied groups was well preserved. 
Their contact with basement membranes, neighbouring granulosa cells and oocytes 
looked similar to that in fresh tissue. They contained an intact nucleus with nucleolus, 
homogeneous euchromatin and peripheral heterochromatin. The cytoplasm of the 
granulosa cells contained undamaged organelles and the endoplasmic reticulum (ER) 
was clearly seen. 
There were clearly visible differences in the preservation of ovarian stromal tissue. 
The stroma was better preserved in vitrified tissue than it was in the slowly frozen 
tissue. Vitrified tissues after both 5 and 10 min of exposure to vitrification solutions had 
uniform and intact collagen fibres. Vitrified tissue samples after 10 min of exposure to 
the vitrification solutions (Vit10) showed the best morphology of stroma. It was 
composed of collagen fibres and spindles-shaped fibroblast- like cells. The longer 
incubation time (10 min) was probably more optimal than the short time incubation 
time (5 min). The nuclei had normal morphology with intact nuclear membranes. Most 
stromal cells contained intact mitochondria and other organelles. The centrioles were 
usually close to the nucleus or the Golgi apparatus. 
After slow freezing with PrOH and EG, the stroma showed cryodamage indicated by 
shrunken stromal cells containing pyknotic nuclei, ruptured cell membranes and 
vacuolization in the ER as a sign of early necrosis. Most of the stromal cells were at 
necrosis and indicated by disruption of nuclear and cellular membranes, organelle 
breakdown and cell lysis. Collagen fibres and extracellular matrix were disrupted.  
Poor preservation of ovarian stroma was clearly found in the slowly frozen tissue with 
PrOH or EG. The viability of the stroma in the vitrified samples was significantly better 
than that in slowly frozen samples. There were no significant differences in the 
morphology of the ovarian stroma in tissue samples vitrified with different incubation 
times.  
 
1.23 ARTICLE II 
In article II, we carried out vitrification of human ovarian tissue in a closed system in 
which the tissue was never in direct contact with liquid nitrogen (LN2), neither during 
vitrification nor during storage in a vapour-phase nitrogen storage freezer. We 
transferred the tissue pieces in a sterile and leak proof cryotube with a minimum 
volume of vitrification medium. The vitrification medium consisted of a mixture or 
cryoprotectants DMSO, PrOH, EG and PVP. The results did not show any differences 
in the light and electron microscopic ultrastructure of oocytes between non-vitrified and 
vitrified tissues. There were no subcellular alterations in the vitrified tissue samples. 
 
Histological analysis on 100 follicles in both non-vitrified (control) and vitrified tissues 
(before culture) was analysed by LM. Of these follicles, 37 were primordial, 42 
primary, 13 secondary and 8 atretic. The morphology of a total of 136 follicles in both 
non-vitrified and vitrified tissues after 24 h culture was also evaluated. Of these 
follicles, 15 were primordial, 66 primary, 12 secondary and 43 atretic. We did not 
found any clear differences in the morphology of follicles and stroma after closed 
vitrification.  
 
Transmission electron microscopy (TEM) was used to analyse the ultrastructural 
changes in ovarian tissue caused by cryoinjury, during vitrification and warming. 
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Ultrastructural alterations of ovarian tissues after vitrification and culture were analysed 
by evaluating the structures of oocytes, granulosa cells and stroma, separately. Forty-
one follicles in both vitrified and non-vitrified tissues were analysed. Of those follicles, 
ten were in tissues from non-vitrified, six from vitrified, 16 from non- vitrified cultured 
and nine from vitrified cultured tissue. 
The ultrastructure of the oocytes in vitrified tissue was similar to that in the fresh tissue. 
The nuclei were dominated by euchromatin. The inner and outer nuclear membranes 
containing distinct nuclear pores were clearly seen. The cytoplasm was well preserved 
showing a homogenous structure without obvious increased vacuolization. The round 
or ovoid shaped mitochondria had highly organised structure with condensed matrix 
and intact cristae. Normal looking endoplasmic reticulum (ER) and mitochondria were 
seen in the oocytes. Golgi complexes were well preserved. The contacts between the 
oocytes and granulosa cells were sharp, and they contained gap junctions and 
microvilli. 
The granulosa cells (GCs) in vitrified tissues had a normal morphology and organelle 
distribution. The nuclei had peripheral aggregates of chromatin. The cytoplasm 
contained mitochondria with cristae, and ER. Microvilli were present and Gap 
junctions connecting neighbouring cells were seen. The GCs showed uniform contact 
without any obvious increased in vacuolization.  
In vitrified tissues, the stroma was well preserved. The viability of the follicles was 
evaluated by culture for 24 hours. The morphology and ultrastructure of the follicles in 
the ovarian tissue after warming and culture was normal. The ultrastructure of the 
follicles in both non-vitrified and vitrified tissues was similar after culture. There were 
neither obvious morphological abnormalities nor necroses in the oocytes after culture. 
Well-defined nuclear pores and well-preserved round-shaped mitochondria and ER 
were seen in the oocytes. The GCs had nuclei with peripheral heterochromatin and a 
large number of rod-shaped mitochondria in their cytoplasm. The stromal cells 
contained hetero- and euchromatic nuclei. After culture, the vitrified tissues had 
elongated stromal cells and large numbers of collagen bundles. 
 
Summarising the results in the article II, we have shown an intact structure of vitrified 
ovarian tissue. Our vitrification method is clinically applicable, because the tissue was 
never in direct contact with liquid nitrogen. The tissue preparation, vitrification, 
banking, warming procedures have been carried out in a closed sterile, traceable 
system, in a controlled and defined sterile environment. This system fulfils the quality 
requirements of the European directives 2004/23, 2006/17/EG and 2006/86/EG and 
Swedish tissue law 2008:286.  
 
1.24 ARTICLE III 
In article III, we studied the occurrence of possible apoptosis in the tissue after 
vitrification. We evaluated the light and electron microscopic morphology of the 
follicles in the vitrified tissues. Human ovarian tissue was vitrified either with a 
solution consisting of a combination of cryoprotectants, DMSO, PrOH, EG and PVP or 
EG and bovine serum albumin (BSA). The results showed that neither of the 
vitrification methods caused apoptosis in primordial nor primary follicles. 
Light microscopic (LM) analysis on 264 follicles showed that the proportion of viable 
follicles per donor before culture was 97.14 ± 7.5 % in fresh, 90.87 ± 10.74% in tissue 
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vitrified with DMSO, PrOH, EG and PVP, and 92.16 ± 8.6% in tissue vitrified with EG 
and BSA. The proportion of viable follicles after equilibration and removal of 
vitrification solution (toxicity test) was 97.43 ± 4.4% in tissue vitrified with DMSO, 
PrOH, EG and PVP, and 95.54 ± 5.98% in tissue vitrified with EG and BSA 
respectively.  
 
Ultrastructural evaluation of the follicles by TEM showed well -preserved morphology 
in both tissues vitrified using DMSO, PrOH, EG and PVP, and EG and BSA. In tissues 
vitrified using any of the methods, the oocytes contained euchromatic nuclei. The 
mitochondria of the oocytes were well preserved.  
The granulosa cells and stromal cells had heterochromatic nuclei. The mitochondria 
of oocytes were well preserved although a few alterations were seen. Fresh and vitrified 
tissues after warming and 24h culture were used for TUNEL assay. There were no 
signs of apoptosis in primordial or primary follicles in either fresh or vitrified groups. 
The fresh and the vitrified tissue after 24h culture did not show any TUNEL-positive 
cells in the primordial or primary follicles. DNA laddering was used to evaluate the 
incidence of apoptosis in ovarian tissue from both fresh and vitrified groups. There was 
no DNA laddering on gel electrophoresis from genomic DNA isolated from fresh or 
vitrified tissues, neither after warming or 24h culture. Taking all the data together, 
vitrification of human ovarian tissue using solutions DMSO, PrOH, EG and PVP, or 
EG and BSA does not cause apoptosis in primordial or primary follicles. 
 
1.25 ARTICLE IV 
In article IV, we evaluated the use of only one permeating protectant, EG, instead of a 
combination of three cryoprotectants, DMSO, PrOH and EG in a closed vitrification 
system, presented earlier by us. Human ovarian tissue was vitrified in closed sealed 
cryotubes using either a combination of cryoprotectants DMSO, PrOH, EG and PVP or 
only EG and human serum albumin (HSA).  
A total of 988 follicles was analyzed by LM. Of these, 584 follicles were evaluated 
before culture and 404 follicles after culture. Table 4 shows the proportion of viable 
follicles from nine donors in ovarian tissue analyzed by LM. There were no clear 
differences in the morphology of the follicles in the tissue vitrified with any of the 
different solutions. There were no significant differences between the fresh and vitrified 
tissue after culture.   
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Light 
microscopy 
Fresh Vitrified 
using DMSO, 
PrOH, EG 
Vitrified 
using 
only EG 
Fresh, 
Cultured 
Vitrified 
using DMSO, 
PrOH, EG- 
Cultured 
Vitrified 
using 
only EG- 
Cultured 
 
Primordial 97 
(51.1) 
113 (57.1) 108 
(55.1) 
47 (24.1) 35 (27.3) 13 (16.0) 
 
Primary 76 (40) 52 (26.3) 62 (31.6) 112 (57.4) 49 (38.3) 41 (50.6) 
 
Secondary 12 
(6.3) 
11 (5.6) 8 (4.1) 16 (8.2) 7 (5.5) 8 (9.9) 
Viable 
follicles 
 
185 
(97) 
176 (89) 178 (91) 175 (90) 91 (71) 62 (77) 
Atretic 
 
5 (2.6) 22 (11.0) 18 (9.2) 20 (10.3) 37 (28.9) 19 (23.5) 
Total no. 
Follicles 
 
190 198 196 195 128 81 
Total F. 
density 
(mm3) 
1838 1149 1511 1957 874 362 
 
 
 
 
 
 
A total number of 77 follicles was evaluated by TEM. The number of follicles found in 
the tissue before culture was nine   in the fresh tissue, 17 in the tissue vitrified with 
DMSO, PrOH, EG and 13 in the tissue vitrified with only EG. Of the follicles found in 
the tissue after culture, were ten in the fresh tissue, 14 in the tissue vitrified   with 
DMSO, PrOH, EG and 14 in the tissue vitrified with only EG.  
 
The results from the evaluation of the ultrastructure of oocytes in vitrified tissues did 
not show any variation between the vitrified or control tissue. There were no cellular 
differences between the tissue vitrified using either of the two solutions, as regards to 
the ultrastructure of mitochondria, microvilli or endoplasmic reticulum (ER) of the 
oocytes. The ER and Golgi apparatus were well defined. The outer and inner nuclear 
membranes with distinct nuclear pores were clearly seen.  
The granulosa cells in tissue vitrified using either DMSO, PrOH, EG or only EG were 
morphologically normal. The nuclei with peripheral aggregates of chromatin, the 
cytoplasm contained organelles such as mitochondria with cristae and ER showed 
normal ultrastructure. The contact between the granulosa cells and the basement 
membrane was well preserved.  
Stromal tissue contained abundant collagen fibres and spindle- shaped fibroblast like 
cells and it appeared to be well preserved in both vitrified groups.  
Follicular viability after warming and 24 h culture was evaluated. There were no 
severe morphological changes or necroses in the oocytes after culture. The granulosa 
Table 4. Numbers of viable follicles from nine donors, within ovarian tissue analysed 
by LM. Values are presented in n (%). 
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cells and stroma appeared to be normal. We used immunostaining for active caspase-3 
for detection of apoptosis in tissue vitrified with either DMSO, PrOH, EG or only EG. 
There was no apoptosis in primordial or primary follicles or stroma cells in either of 
vitrification methods. 
There were no significant differences, in the electron microscopic scores of oocytes, 
granulosa cells or stromal cells, between the two vitrification solutions. According to 
the results, the oocytes, granulosa cells and stromal cells were equally well preserved in 
tissue vitrified with either vitrification solution. 
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6 GENERAL DISCUSSION  
 
 
 
Fertility preservation by cryopreservation of ovarian cortical tissue is an excellent 
option for pre-pubertal girls and young women at risk of premature ovarian failure 
because of cancer therapy or genetic disorders. There are two methods for 
cryopreserving ovarian tissue, slow freezing and vitrification. Our group has earlier 
developed a slow freezing method for cryopreserving human ovarian tissue using PrOH 
and sucrose as cryoprotectants (Hovatta et al. 1996; Hreinsson et al. 2003). Other 
permeating cryoprotectants such as DMSO and EG have been also used in slow 
freezing of human ovarian tissue (Hovatta et al. 1996; Newton et al. 1996; Oktay et al. 
1997; Schmidt et al. 2003).  Auto-transplantation of post-thawed ovarian tissue has 
resulted in live births worldwide (Dolmans et al. 2013). In spite of successful 
preservation of oocytes and granulosa cells, poor survival of stromal tissue after slow 
freezing is a limitation.  
We carried out the first systematic comparison between cryopreservation of human 
ovarian tissue by slow freezing and vitrification.  
 
Vitrification is a method for cryopreservation of ovarian tissue without ice crystal 
formation. It results in good morphology. In our comparative study (Article I) we 
showed that ovarian stroma was better preserved by using vitrification than it was after 
slow freezing. There has been limited data regarding comparison of vitrification and 
slow freezing of human ovarian tissue, and contradictory conclusions have drawn by 
researchers. Some results have suggested that cryopreservation of human ovarian tissue 
by using slow freezing is more efficient than vitrification (Gandolfi et al. 2006; 
Isachenko et al. 2007).  Some other authors concluded that modified vitrification is an 
effective method for freezing human ovarian tissue because it showed a high rate of 
normal follicles after warming (Li et al. 2007). These different results may be due to 
differences in the procedure such as concentrations and composition of cryoprotectants, 
exposure time to the cryoprotectants and the rate of cooling.   
Our vitrification procedure was improved at many points compared to those used 
earlier. The vitrification solution we used in the comparative study consisted of a 
combination of DMSO, PrOH and EG diluted in serum-free medium (Article I). The 
concentration of each cryoprotectant was gradually increased from 2.5% (total 
concentration of cryoprotectant 7.5%) at the first incubation step to 15% at the second 
and 10% (total 30%) at the final step. At this step non-permeating cryoprotectant, PVP 
was also added. Hence, the final overall concentration of cryoprotectants in the 
vitrification solution was 40%. The third step was carried out in 4°C to reduce the 
toxicity of cryoprotectants at high concentrations.  To increase the rate of vitrification 
in the first study, an open system was used. Insemination cryostraws cut by scalpel 
were utilised. In every study in this thesis, we used tissue culture to evaluate the 
function and the viability of the follicles after thawing/warming because the initiation 
of follicular growth is a fast and safe event.  It can be used as a method to evaluate the 
viability of follicles. (Hovatta et al. 1997). The cryoinjury in the tissue was evaluated 
by ultrastructural analysis, which gives more detailed information about ultrastructural 
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changes in the cell than LM (Hreinsson et al. 2003; Martinez-Madrid et al. 2007). 
Preservation of ovarian tissue including oocytes, granulosa cells and stroma depends on 
the composition and exposure time to cryopreservation media and the rate of cooling 
and thawing. Ovarian stromal tissue frozen by slow freezing was poorly preserved 
showing loss of plasma membrane, increased chromatin condensation, lysis of stromal 
cells, vacuolization and disintegration of ovarian stroma (Hreinsson et al. 2003; Eyden 
et al. 2004). Our observations were in line with these results. There are many variables 
involved in vitrification processes that affect the effectiveness and the potential of 
survival rates of the cells/ tissues.  The type and concentration of CPA, sample size, 
carrier system, the temperature of exposure to vitrification solution and the exposure 
time to the final solution are such factors (Liebermann et al. 2002). The size of ovarian 
tissue pieces plays an important role in a successful vitrification outcome. It would take 
a longer time for CPAs to penetrate to a lager ovarian fragment and reach to the inner 
part of the tissue. It would result in overexposure of the cells on the surface by CPAs 
and cause damages due to the toxicity of high CPA concentration. The use of smaller 
ovarian fragments allows faster cooling and warming rates, hence avoiding ice crystal 
formation and decreasing the cryoinjury. In all four studies, we used small size of 
ovarian tissue fragments (about 1- 1.5mm3) in order to increase the cooling rate.  
 
However, direct contact of the tissue with liquid nitrogen in an open system is not 
optimal for freezing human ovarian tissue because of the possible risk of 
contamination. In the next study, we performed vitrification in a clinical grade closed 
system in which human ovarian tissue is never in direct contact with liquid nitrogen, 
neither during the vitrification procedure nor during storage (Article II). The device that 
was used in this study was a cryotube, containing internal thread with silicon gasket to 
provide the best possible seal. The long exposure time of the cryoprotectants was 
applied because our earlier study (Article I) showed a good- quality of stroma with 
collagen fibres and stromal cells after 10 min of incubation. Stromal cells probably play 
an essential role in proliferation and differentiation of granulosa cells (Hovatta et al. 
1999; Liu et al. 2000). Interaction between granulosa cells, stromal cells and oocytes is 
important for ovarian function (Hovatta 2005). Hence, preservation of the integrity of 
these components is necessary (Gook et al. 2004). Our observations from LM showed 
similar morphology of follicles in both vitrified and fresh tissue. This observation was 
confirmed by TEM analysis, which revealed that the structure of organelles of 
granulosa cells, and oocytes were well preserved in vitrified tissue. The results in this 
study suggested that human ovarian tissue can be well preserved in a closed system 
using a cryotube.  
Our next aim was to develop an even simpler and more reliable clinical grade 
vitrification procedure for human ovarian tissue. Hence, we decided to study the 
possible use of only one permeating cryoprotectant, EG, instead of a combination of 
three permeating cryoprotectants DMSO, PrOH and EG in clinical human ovarian 
vitrification. We chose EG because it has been shown to give good morphology in 
vitrification of mouse ovarian follicles (Salehnia 2002). In order to apply a clinical 
grade vitrification in study IV, we used HSA instead of BSA that was used in study III. 
Bovine serum albumin as an animal protein is not optimal when used clinically in 
human, since there is risk of transmitting pathogens such as prions.  Moreover, the cells 
take non-human proteins from the culture medium. Such proteins may make the cells 
immunogenic and cause immunoreactions (Martin et al. 2005; Unger et al. 2008). An 
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open system was used in study III, since after vitrification the vitrified tissues were 
stored in liquid nitrogen but in study IV, the system was a closed one. 
The morphology of the oocytes, granulosa cells and stromal cells in tissue after both 
vitrification methods were analysed. The LM and TEM showed that the morphology 
after both vitrification methods in both cultured and non-cultured tissue was similar. No 
signs of apoptosis were observed when using the TUNEL assay and DNA laddering 
(Article III). In addition, immunostaining for active caspase-3 did not show any 
apoptosis in neither primordial nor primary follicles nor stromal cells (Article IV). This 
was expected, because the cryoinjury is caused by small ice crystals that damage the 
membrane in the cells and cellular organelles, and not clearly by apoptosis. Our results 
suggested that vitrification solution with only one permeating cryoprotectant, EG in 
diluted human serum albumin, instead of three cryoprotectants, can be recommended in 
vitrification of human ovarian tissue. It is a fast, simple and safe procedure that can be 
carried out at clinical setting.   
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7  CONCLUSIONS 
 
• Vitrification of human ovarian tissue is more efficient than slow freezing in 
maintaining the cellular morphology. The stroma of vitrified ovarian tissue is 
better preserved than that cryo-stored by slow freezing. 
 
• Closed vitrification of human ovarian tissue without direct contact with liquid 
nitrogen is as good as open vitrification used earlier. It can be performed in a 
clinical setting. 
 
 
• The clinically feasible vitrification method can be further simplified by using 
only one permeating cryoprotectant, EG instead of a combination of DMSO, 
PrOH and EG. 
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